NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies

Active Not RecruitingPhase 1

Sponsor: AstraZeneca

Conditions: Tumor, Cancer

Interventions: AZD6244

Countries: United States, Netherlands, United Kingdom

The primary purpose of the study is to assess the safety, tolerability and pharmacokinetics of a capsule of AZD6244 in participants with advanced solid malignancies.

Eligibility overview

Sex: ALL

Age: 18 Years to 99 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* cancer which is refractory to standard therapies
* World Health Organization (WHO) performance status 0 to 2
* evidence of post-menopausal status or negative pregnancy test

Exclusion Criteria:

* Radiotherapy/chemotherapy within 21 days prior to entry
* brain metastases/spinal cord compression unless stable off steroids/anticonvulsants
* evidence of severe/uncontrolled systemic disease
* participated in an investigational drug study within 30 days

Locations (4)

Aurora, Colorado, United States
Nijmegen, Netherlands
Utrecht, Netherlands
Sutton, United Kingdom